Baidu
map

J Altern Complement Med:美药剂师发现中药若与常规药物混服或致命

2012-05-10 网易探索 网易探索

具有治疗功效的生姜,是一种较为流行的天然补充剂。 美国药剂师凯瑟琳·乌尔布里奇经研究发现,如果将草药和补充疗法与常规药物混合在一起,可能将患者的生命置于危险境地。研究显示天然补充剂与广泛使用的药物混合服用将产生有害的副作用并引发一系列健康问题。 英国约有1000万人常把草药、维生素和矿物质补充剂混服 乌尔布里奇的研究发现,大蒜、生姜、贯叶连翘(圣约翰草)、绿茶等流行的补充剂能够对处方药或者非


具有治疗功效的生姜,是一种较为流行的天然补充剂。

美国药剂师凯瑟琳·乌尔布里奇经研究发现,如果将草药和补充疗法与常规药物混合在一起,可能将患者的生命置于危险境地。研究显示天然补充剂与广泛使用的药物混合服用将产生有害的副作用并引发一系列健康问题。

英国约有1000万人常把草药、维生素和矿物质补充剂混服

乌尔布里奇的研究发现,大蒜、生姜、贯叶连翘(圣约翰草)、绿茶等流行的补充剂能够对处方药或者非处方药的药效产生不利影响。她指出这种“混搭”对年轻人、老年人以及存在多种健康问题,需要服用大量药物的人危害最大,孕妇和哺乳期妇女的健康也会因此陷入危险之中。

乌尔布里奇曾撰写几部有关草药的著作。她指出医生需要让患者了解任何潜在风险,避免因服用天然补充剂对身体造成危害,甚至危及生命。在发表于《替代和补充医学杂志》上的研究论文中,乌尔布里奇表示:“天然并不等于安全。如果某种物质能够在人体内产生治疗功效,这种物质也会引发不利于健康的反应或者交互作用。”

小白菊、生姜、银杏与阿司匹林等同服会有危险副作用

根据她的研究发现,小白菊、生姜、银杏等流行的天然补充剂均含有能够降血压或者稀释血液的营养物质,但在与阿斯匹林和华法林发生相互作用时便会带来严重健康风险。目前有数百万患者服用阿斯匹林和华法林,预防心脏病发作。此外,功能饮料或者营养棒与药物混合服用也会导致危险的副作用。

葡萄柚汁能抑制肠道中分解药物的酶的功效

乌尔布里奇警告称,可起到降血压功效的大蒜补充剂能够对抗凝血药和用于预防移植排斥反应的免疫抑制剂环孢霉素的药效产生不利影响。此外,葡萄柚汁和药物也能发生相互作用,可能抑制通常在肠道内将药物分解的酶的作用。一杯葡萄柚汁在体内的存在时间可超过24小时,患者在服用他汀类、抗高血压、精神病治疗药物以及万艾可(伟哥)期间不应喝葡萄柚汁。

缬草会加强麻醉药剂的药效,贯叶连翘会让移植器官者出现排斥反应

乌尔布里奇指出,安眠药的天然替代品缬草能够加强麻醉剂的药效,用于治疗抑郁症的贯叶连翘能够与免疫抑制剂发生相互作用,导致出现移植排斥反应。外科医生表示,如果患者不在手术前一两周或者术后服用血液稀释剂等处方药期间摄入草药制品,绝大多数与手术有关的副作用都可避免。

doi:10.1089/act.2012.18202
PMC:
PMID:

What Every Clinician Should Know About Herb–Supplement–Drug Interactions

Ulbricht Catherine

Ulbricht Catherine. Alternative and Complementary Therapies. April 2012, 18(2): 67-70. doi:10.1089/act.2012.18202. Published in Volume: 18 Issue 2: April 20, 2012 Catherine Ulbricht, PharmD Natural Standard Research Collaboration, is a senior attending pharmacist at Massachusetts General Hospital, and is an adjunct/assistant clinical professor at many universities.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783538, encodeId=76c71e835383b, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Sep 07 20:49:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779699, encodeId=950f1e7969978, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 09 10:49:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860944, encodeId=4fb6186094469, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 18 17:49:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773150, encodeId=c4801e7315006, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Fri Nov 09 16:49:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604648, encodeId=ad4b1604648c9, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605713, encodeId=aec41605e1336, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
    2012-09-07 zsyan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783538, encodeId=76c71e835383b, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Sep 07 20:49:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779699, encodeId=950f1e7969978, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 09 10:49:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860944, encodeId=4fb6186094469, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 18 17:49:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773150, encodeId=c4801e7315006, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Fri Nov 09 16:49:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604648, encodeId=ad4b1604648c9, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605713, encodeId=aec41605e1336, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
    2012-10-09 w363522449
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783538, encodeId=76c71e835383b, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Sep 07 20:49:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779699, encodeId=950f1e7969978, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 09 10:49:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860944, encodeId=4fb6186094469, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 18 17:49:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773150, encodeId=c4801e7315006, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Fri Nov 09 16:49:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604648, encodeId=ad4b1604648c9, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605713, encodeId=aec41605e1336, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
    2012-09-18 shizhenshan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783538, encodeId=76c71e835383b, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Sep 07 20:49:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779699, encodeId=950f1e7969978, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 09 10:49:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860944, encodeId=4fb6186094469, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 18 17:49:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773150, encodeId=c4801e7315006, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Fri Nov 09 16:49:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604648, encodeId=ad4b1604648c9, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605713, encodeId=aec41605e1336, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
    2012-11-09 xuyong536
  5. [GetPortalCommentsPageByObjectIdResponse(id=1783538, encodeId=76c71e835383b, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Sep 07 20:49:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779699, encodeId=950f1e7969978, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 09 10:49:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860944, encodeId=4fb6186094469, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 18 17:49:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773150, encodeId=c4801e7315006, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Fri Nov 09 16:49:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604648, encodeId=ad4b1604648c9, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605713, encodeId=aec41605e1336, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]
    2012-05-12 贵阳
  6. [GetPortalCommentsPageByObjectIdResponse(id=1783538, encodeId=76c71e835383b, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Sep 07 20:49:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779699, encodeId=950f1e7969978, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 09 10:49:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860944, encodeId=4fb6186094469, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Sep 18 17:49:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773150, encodeId=c4801e7315006, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Fri Nov 09 16:49:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604648, encodeId=ad4b1604648c9, content=<a href='/topic/show?id=decf8e3276c' target=_blank style='color:#2F92EE;'>#药剂师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87327, encryptionId=decf8e3276c, topicName=药剂师)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8719252633, createdName=贵阳, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605713, encodeId=aec41605e1336, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 12 04:49:00 CST 2012, time=2012-05-12, status=1, ipAttribution=)]

相关资讯

Am J Pathol:基因异常预测前列腺癌复发

良性或恶性组织中的基因异常预测前列腺癌复发,一项有关更高效、准确技术的研究论文发表在American Journal of Pathology杂志上。 2012年5月7日,主动监测50岁以上的血清前列腺特异性抗原(PSA)的水平已大大提高了前列腺癌的早期检测,但诊断后临床结果的预测仍然是一个重大的挑战。匹兹堡大学医学院的研究人员发现在前列腺癌以及相邻的肿瘤良性前列腺组织和前列腺癌患者血液中一个基

Baidu
map
Baidu
map
Baidu
map